Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective
Gilda Varricchi(University of Naples Federico II), Carlo G. Tocchetti(Federico II University Hospital), Rosalinda Madonna(University of Chieti-Pescara), Giancarlo Marone(Federico II University Hospital), Pietro Ameri(Ospedale Policlinico San Martino), Alessandra Ghigo(University of Turin), Christian Cadeddu Dessalvi(University of Cagliari), Pasquale Pagliaro(Ospedale San Luigi Gonzaga), Ines Monte(University of Catania), Concetta Zito(University of Messina), Giuseppe Mercuro(University of Cagliari), Valentina Mercurio, Paolo Parrella(University of Naples Federico II), Antonio Pecoraro(University of Naples Federico II), Paolo Spallarossa(Ospedale Policlinico San Martino), Giuseppina Novo(AOL (United States)), Flora Pirozzi(University of Naples Federico II)
Cited by 154
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
|European Heart Journal|2024|2.4k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal - Cardiovascular Imaging|2022|486
Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)
|European Journal of Heart Failure|2020|364